Balaglitazone|CAS 199113-98-9|DC Chemicals

Cas No.:	199113-98-9
Chemical Name:	DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344
Synonyms:	DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344
SMILES:	O=C(N1)SC(CC2=CC=C(OCC(N3C)=NC4=C(C=CC=C4)C3=O)C=C2)C1=O
Formula:	C₂₀H₁₇N₃O₄S
M.Wt:	395.4317

Description:	Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
In Vivo:	Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPARγ agonist rosiglitazone[1]. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone[3].
In Vitro:	Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM[1]. Balaglitazone (5-100 μM) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC50s of 0.117 μM and 0.53 μM, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 µM) increases Rh123 accumulation in K562/DOX cells, but does not increases MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition[2].

Cat. No.	Product name	Field of application
DC77017	9(10)-Nitrooleate	9(10)-Nitrooleate（NOA）is an endogenous nitrated fatty acid that functions as a highly efficient bioactive molecule. Its primary role is the specific inhibition of the STING protein, a key inflammatory signaling sensor within cells. When STING is aberrantly activated, it can trigger a severe inflammatory response, leading to cellular damage.Mechanistically, NOA acts as an electrophile, capable of covalently modifying specific cysteine residues on the STING protein, thereby effectively blocking its ability to activate downstream signaling pathways. This inhibitory action establishes NOA as a potent endogenous anti-inflammatory agent. In practical application, loading NOA into delivery systems, such as lipid nanoparticles, equips them with an intrinsic "molecular fire extinguisher." It significantly mitigates the acute inflammatory response triggered by delivered cargo, effectively transforming otherwise toxic delivery vehicles into safe platforms. The core value of NOA lies in its ability to provide exceptional safety without compromising the functional expression of therapeutic payloads, offering a crucial safeguard for achieving long-term treatments.
DC9602	Balaglitazone	Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.
DC7412	R(+)-Etomoxir (sodium salt)	A PPARα agonist and an irreversible CPT-1 inhibitor.
DC1034	WY14643 (Pirinixic Acid)	WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with ED50 of 1.5 μM.
DC10700	Seladelpar	Seladelpar is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist.
DC12034	MA-0204	MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.
DC2079	GW-9662	GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.
DC4233	GW501516	GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.
DC9904	GW0742	GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
DC2078	GW-7647	GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.